These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 2887616)

  • 41. Selective and competitive histamine H2-receptor blocking effect of famotidine on the blood pressure response in dogs and the acid secretory response in rats.
    Miyata K; Kamato T; Fujihara A; Takeda M
    Jpn J Pharmacol; 1990 Oct; 54(2):197-204. PubMed ID: 1981794
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of the effects of over-the-counter famotidine and calcium carbonate antacid on postprandial gastric acid. A randomized controlled trial.
    Feldman M
    JAMA; 1996 May; 275(18):1428-31. PubMed ID: 8618369
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cimetidine versus famotidine: the effect on the pharmacokinetics of theophylline in rats.
    Mojaverian P; Rocci ML; Saccar CL; Vlasses PH; Ferguson RK
    Eur J Drug Metab Pharmacokinet; 1985; 10(2):155-9. PubMed ID: 2864251
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impaired bioavailability of famotidine given concurrently with a potent antacid.
    Barzaghi N; Gatti G; Crema F; Perucca E
    J Clin Pharmacol; 1989 Jul; 29(7):670-2. PubMed ID: 2569486
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of famotidine with cimetidine and ranitidine.
    Berardi RR; Tankanow RM; Nostrant TT
    Clin Pharm; 1988 Apr; 7(4):271-84. PubMed ID: 2896559
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A pharmacokinetic profile of nizatidine in man.
    Callaghan JT; Bergstrom RF; Rubin A; Chernish S; Crabtree R; Knadler MP; Obermeyer B; Offen WW; Schneck DW; Aronoff G
    Scand J Gastroenterol Suppl; 1987; 136():9-17. PubMed ID: 2892261
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The antisecretory effects of zaltidine, a novel long-acting H2-receptor antagonist, in healthy volunteers and in subjects with a past history of duodenal ulcer.
    Laferla G; Buchanan N; Hearns J; Crean GP; McColl KE; Clucas AT
    Br J Clin Pharmacol; 1986 Oct; 22(4):395-9. PubMed ID: 2876724
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Differences in the antisecretory actions of the proton pump inhibitor AG-1749 (lansoprazole) and the histamine H2-receptor antagonist famotidine in rats and dogs.
    Nagaya H; Inatomi N; Satoh H
    Jpn J Pharmacol; 1991 Apr; 55(4):425-36. PubMed ID: 1886288
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibition of gastric secretion by a new H2-antagonist, YM-11170 in healthy subjects.
    Miwa M; Tani N; Miwa T
    Int J Clin Pharmacol Ther Toxicol; 1984 Apr; 22(4):214-7. PubMed ID: 6325352
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interaction of ranitidine and famotidine with guinea pig-isolated parietal cells.
    Sewing KF; Hannemann H
    Pharmacology; 1986; 33(5):274-8. PubMed ID: 2432626
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacology of H2-receptor antagonists: an overview.
    Schunack W
    J Int Med Res; 1989; 17 Suppl 1():9A-16A. PubMed ID: 2566544
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intravenous nizatidine kinetics and acid suppression.
    Callaghan JT; Bergstrom RF; Obermeyer BD; King EP; Offen WW
    Clin Pharmacol Ther; 1985 Feb; 37(2):162-5. PubMed ID: 2857117
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effects of famotidine, 40 mg at night, on 24-hour intragastric acidity and plasma gastrin concentration in healthy subjects.
    Lanzon-Miller S; Pounder RE; Ball SG; Dalgleish DJ; Coward J; Jackson AO
    Scand J Gastroenterol; 1988 Mar; 23(2):244-50. PubMed ID: 3283919
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Effect of a new H2 receptor antagonist, famotidine, on gastric secretion].
    Noci MT; Coruzzi G
    Boll Soc Ital Biol Sper; 1986 Sep; 62(9):1103-9. PubMed ID: 2879549
    [No Abstract]   [Full Text] [Related]  

  • 55. Studies on MK-208 (YM-11170) a new, slowly dissociable H2-receptor antagonist.
    Pendleton RG; Torchiana ML; Chung C; Cook P; Wiese S; Clineschmidt BV
    Arch Int Pharmacodyn Ther; 1983 Nov; 266(1):4-16. PubMed ID: 6141772
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetic and gastric secretory studies of ranitidine in man.
    Louis WJ; Mihaly GW; Hanson RG; Anderson A; McNeil JJ; Yeomans ND; Smallwood RA
    Scand J Gastroenterol Suppl; 1981 Jun; 69():11-7. PubMed ID: 6119773
    [TBL] [Abstract][Full Text] [Related]  

  • 57. H2-antagonists and motility of the upper gastrointestinal tract in man.
    Dobrilla G; de Pretis G; Comberlato M; Amplatz S
    Hepatogastroenterology; 1988 Feb; 35(1):30-3. PubMed ID: 2896148
    [No Abstract]   [Full Text] [Related]  

  • 58. YM022, a potent and selective gastrin/CCK-B receptor antagonist, inhibits peptone meal-induced gastric acid secretion in Heidenhain pouch dogs.
    Yuki H; Nishida A; Miyake A; Ito H; Akuzawa S; Takinami Y; Takemoto Y; Miyata K
    Dig Dis Sci; 1997 Apr; 42(4):707-14. PubMed ID: 9125636
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of the novel histamine H2-antagonist 5,6-dimethyl-2-[4-[3-(1- piperidinomethyl)phenoxy]-(z)-2-butenylamino]-4(1H)-pyrimidine dihydrochloride on histamine-induced gastric acid secretion in Heidenhain pouch dogs.
    Uchida M; Ohba S; Ikarashi Y; Misaki N; Kawano O
    Arzneimittelforschung; 1993 Aug; 43(8):873-6. PubMed ID: 8105784
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of prolonged oral cimetidine, ranitidine, and famotidine therapy on antipyrine elimination.
    Sakaue H; Akamatsu K; Hirabayashi Y; Sasaki T; Nakanishi K; Okada S; Kanaoka M; Nishinobu M; Masumoto S; Ohta Y
    Clin Ther; 1987; 9(6):602-6. PubMed ID: 2894244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.